Compare · CAH vs SCNX
CAH vs SCNX
Side-by-side comparison of Cardinal Health Inc. (CAH) and Scienture Holdings Inc. (SCNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAH and SCNX operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- CAH is the larger of the two at $45.64B, about 2873.7x SCNX ($15.9M).
- Over the past year, CAH is up 25.3% and SCNX is down 55.5% - CAH leads by 80.8 points.
- SCNX has been more active in the news (5 items in the past 4 weeks vs 1 for CAH).
- CAH has more recent analyst coverage (25 ratings vs 0 for SCNX).
- Company
- Cardinal Health Inc.
- Scienture Holdings Inc.
- Price
- $194.83-0.14%
- $0.38-3.96%
- Market cap
- $45.64B
- $15.9M
- 1M return
- -0.20%
- -4.78%
- 1Y return
- +25.29%
- -55.52%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 1
- 5
- Recent ratings
- 25
- 0
Cardinal Health Inc.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Latest CAH
- SEC Form SD filed by Cardinal Health Inc.
- Cardinal Health Board of Directors Approves Quarterly Dividend
- SEC Form 10-Q filed by Cardinal Health Inc.
- Cardinal Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook
- William Blair initiated coverage on Cardinal Health
- SEC Form 4 filed by Hall Patricia Hemingway
- Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings
- Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies
- Amendment: SEC Form SCHEDULE 13G/A filed by Cardinal Health Inc.
Latest SCNX
- SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Leadership Update
- Scienture Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
- SEC Form 10-Q filed by Scienture Holdings Inc.
- Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
- SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Scienture Holdings Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Amendment: SEC Form 10-K/A filed by Scienture Holdings Inc.